Urology And Neuromodulation Will Likely Drive Boston Scientific's Near Term Growth

Boston Scientific (NYSE:BSX) recently posted a better than expected Q2 performance with a low-double digit revenue growth and 9% jump in adjusted EPS, led by a robust growth across all segments. The company has raised its revenue guidance, and it now expects the growth to be in the range of...